Alector, Inc.
Status: Publicly traded
Direct answer
Alector, Inc. is publicly traded on NASDAQ under the ticker ALEC.
Alector, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering new treatments for neurodegenerative disorders. A key program in its pipeline is AL001, a humanized recombinant monoclonal antibody currently undergoing Phase III clinical trials. This investigational therapy targets a range of severe conditions, including frontotemporal dementia, Alzheimer's disease, Parkinson's disease, and...
Can you invest in Alector, Inc.?
Yes. Alector, Inc. trades publicly on NASDAQ as ALEC.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Alector, Inc.
Detailed equity research is provided by MarketSnap.